Matt Furlow, Principal Associate at ZS

On this episode, hosts Scott and Sarah are joined by Matt Furlow, Associate Principal at ZS, about the evolving role of radiopharmaceuticals in oncology. With a PhD in bioengineering and a decade of consulting experience, Matt brings a unique perspective on how scientific insight and strategic planning intersect to help biotech and pharma companies bring new therapies to the market.Matt shares how radiopharmaceuticals are following a path similar to antibody-drug conjugates and cell therapies. Which is attracting investment but facing challenges in logistics, site readiness, and workforce shortages. He explains why supply chain planning must start early, how regulatory requirements impact delivery sites, and why expanding access is critical for patient care. From radionuclide shortages to limited site accreditation, Matt outlines the practical hurdles companies must overcome.The trio explores emerging isotopes like actinium and copper and the potential for radiopharmaceuticals to move into earlier lines of treatment. Emphasizing the need for a diverse therapeutic toolkit—tailored isotopes, targeting agents, and delivery mechanisms—to personalize cancer care. Matt closes with a bold vision: if key barriers can be addressed, radiopharmaceuticals could one day supplant traditional radiation therapy. —-----Time Stamps:*(02:37) Matt's Journey from Academia to Consulting*(05:29) The Current State of Radiopharmaceuticals*(08:34) Challenges found in the Radiopharmaceutical Supply Chain*(12:14) Exploring the Patient Journey and Logistics*(23:56) What is the Future of Radiopharmaceuticals?--------‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.--------Links:Follow MattVisit ZSTalkradioisotopes.com—----